Abstract:Cancer is a leading cause of death worldwide, resulting in ∼10 million deaths in 2020. Major oncogenic effectors are the Myc proto-oncogene family, which consists of three members including c-Myc, N-Myc, and L-Myc. As a pertinent example of the role of the Myc family in tumorigenesis, amplification of MYCN in childhood neuroblastoma strongly correlates with poor patient prognosis. Complexes between Myc oncoproteins and their partners such as hypoxia-inducible factor-1α and Myc-associated protein X (MAX) result in proliferation arrest and pro-proliferative effects, respectively. Interactions with other proteins are also important for N-Myc activity. For instance, the enhancer of zest homolog 2 (EZH2) binds directly to N-Myc to stabilize it by acting as a competitor against the ubiquitin ligase, SCFFBXW7, which prevents proteasomal degradation. Heat shock protein 90 may also be involved in N-Myc stabilization since it binds to EZH2 and prevents its degradation. N-Myc downstream-regulated gene 1 (NDRG1) is downregulated by N-Myc and participates in the regulation of cellular proliferation via associating with other proteins, such as glycogen synthase kinase-3β and low-density lipoprotein receptor-related protein 6. These molecular interactions provide a better understanding of the biologic roles of N-Myc and NDRG1, which can be potentially used as therapeutic targets. In addition to directly targeting these proteins, disrupting their key interactions may also be a promising strategy for anti-cancer drug development. This review examines the interactions between the Myc proteins and other molecules, with a special focus on the relationship between N-Myc and NDRG1 and possible therapeutic interventions. SIGNIFICANCE STATEMENT: Neuroblastoma is one of the most common childhood solid tumors, with a dismal five-year survival rate. This problem makes it imperative to discover new and more effective therapeutics. The molecular interactions between major oncogenic drivers of the Myc family and other key proteins; for example, the metastasis suppressor, NDRG1, may potentially be used as targets for anti-neuroblastoma drug development. In addition to directly targeting these proteins, disrupting their key molecular interactions may also be promising for drug discovery.

Data from Combinatorial Regulation of Neuroblastoma Tumor Progression by N-Myc and Hypoxia Inducible Factor HIF-1α

Abstract C15: Combinatorial Regulation of Neuroblastoma Tumor Progression by HIF1α and N-myc Transcriptional Factors

Supplementary Table 1, Figures 1-6 from Combinatorial Regulation of Neuroblastoma Tumor Progression by N-Myc and Hypoxia Inducible Factor HIF-1α

Data from WDR5 Supports an N-Myc Transcriptional Complex That Drives a Protumorigenic Gene Expression Signature in Neuroblastoma

MYCN drives glutaminolysis in neuroblastoma and confers sensitivity to an ROS augmenting agent

Mutations That Disrupt PHOXB Interaction with the Neuronal Calcium Sensor HPCAL1 Impede Cellular Differentiation in Neuroblastoma

Wdr5 Supports An N-Myc Transcriptional Complex That Drives A Protumorigenic Gene Expression Signature In Neuroblastoma

N-MYC promotes cell proliferation through a direct transactivation of neuronal leucine-rich repeat protein-1 ( NLRR1 ) gene in neuroblastoma

Data from NLRR1 Enhances EGF-Mediated <i>MYCN</i> Induction in Neuroblastoma and Accelerates Tumor Growth <i>In Vivo</i>

Myc Activation Through Enhancer Hijacking Or Focal Enhancer Amplification Drives A Subset Of High-Risk Pediatric Neuroblastoma

MYC Drives a Subset of High-Risk Pediatric Neuroblastomas and is Activated Through Mechanisms Including Enhancer Hijacking and Focal Enhancer Amplification.

Abstract 2593: A MYCN-independent mechanism mediating secretome reprogramming and metastasis in MYCN-amplified neuroblastoma

MYCN Amplification and ATRX Mutations Are Incompatible in Neuroblastoma

Retraction Note: HNF4A-AS1/hnRNPU/CTCF Axis As a Therapeutic Target for Aerobic Glycolysis and Neuroblastoma Progression.

A Review of the Regulatory Mechanisms of N-Myc on Cell Cycle

Myc Promotes Glutaminolysis in Human Neuroblastoma Through Direct Activation of Glutaminase 2

HIF2α negatively regulates MYCN protein levels and promotes a low-risk noradrenergic phenotype in neuroblastoma.

Conditional Activation of c-MYC in Distinct Catecholaminergic Cells Drives Development of Neuroblastoma or Somatostatinoma

Epigenetic regulation of cell state by H2AFY governs immunogenicity in high-risk neuroblastoma

A MYCN-independent mechanism mediating secretome reprogramming and metastasis in MYCN -amplified neuroblastoma

The Myc Family and the Metastasis Suppressor NDRG1: Targeting Key Molecular Interactions with Innovative Therapeutics